IL22 and psoriasis: These results were confirmed in the IMQ ‘in vivo' murine psoriasis model, in which the hyperproliferation and inflammation were IL-22/STAT3 dependent.40 In fact, the concurrent treatment with LUT-7G led to reduced expression of proliferation markers, increased production of markers of differentiation, and to a phenotypic improvement.